Scholar Rock Holding Corporation (NASDAQ:SRRK) has disclosed the presentation intended for the 43rd Annual J.P. Morgan Healthcare Conference in a recent filing with the U.S. Securities and Exchange ...

IgG MoDE Degraders: BHV-1300 Phase 1 completing last remaining dose cohorts with the optimized subcutaneous formulation with expected completion in 1H 2025. BHV-1310 first-in-human study anticipated ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal ...

Explore how inhibiting myostatin can promote muscle mass in men, addressing sarcopenia, GLP-1 medication effects, and aging ...

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in ...

Ibio Inc. has expanded its cardiometabolic and obesity treatment development program by in-licensing a long-acting anti-myostatin antibody from Astralbio Inc. The antibody, now named IBIO-600, was ...

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...

IBIO-600 showed potent myostatin inhibition in preclinical studies, with clinical trials in obesity planned for 2026. Get Real-Time News and Alerts for Your Portfolio In March, iBio collaborated ...

Calcitonin gene-related peptide (CGRP) inhibitors are now considered a first-line treatment used to treat and prevent migraines. There are two types of CGRP medications: monoclonal antibodies and ...

The prospects of a new class of Duchenne muscular dystrophy therapies have taken another downturn after Roche abandoned development of RG6206, a myostatin inhibitor. The Swiss group revealed the ...

Selective serotonin reuptake inhibitors, or SSRIs, were the third class or generation of antidepressants developed. They are now the most commonly prescribed antidepressant medications. They are ...

potentially reducing side effects compared to traditional myostatin inhibitors. Financially, Scholar Rock is well-positioned with a market cap of $4.19bn and a cash runway extending past initial ...